

SYNTHESIS OF PYRAZOLO [3',4':4,5] PYRIMIDO [2,3-c][1,4] BENZOXAZINES: A NEW HETEROCYCLIC RING SYSTEM

P.S.N. Reddy and Pragati Reddy

Department of Chemistry, Osmania University, Hyderabad-500 007, India,
E-mail: psnreddy@yahoo.com

and

G. Jagath Reddy * and K. Srinivasa Rao


R & D Laboratories, Dr. Jagath Reddy's Heterocyclics, 81, S.V.Co-op Industrial Estate, Balanagar, Hyderabad – 500 037, India. E-mail-jagathreddy@usa.net; Fax # 91-40-23773487.

Abstract

A series of 4-oxo-pyrazolo[3',4':4,5]pyrimido[2,3-c][1,4]benzoxazines(4a-l) have been prepared by cyclocondensation of 1,4-benzoxazinones (1) and with 5-aminopyrazole-4-carboxylic acids(3a-c) in a single step.

Introduction

A number of 1,4-benzoxazines have been reported to possess pharmacological properties such as antimicrobial, cardiogenic, adrenoceptor and antiparasitic activities¹⁻⁴. These observations created interest in the synthesis of 1,4-benzoxazine fused heterocycles like imidazo-⁵, triazolo-⁶, triazino-⁷ and pyridobenzoxazines⁸ with a view to obtain new systems with enhanced biological profile. Furthermore, a wide variety of pyrazoles and fused pyrazoles exhibited analgesic, antipyretic and antiinflammatory activities⁹. Also, several pyrazolopyrimidines are known as potential bactericidal, fungicidal and phosphodiesterase inhibiting agents¹⁰. In view of this and in continuation of our work on new heterocyclic systems¹¹, we now report the synthesis of another new tricyclic system namely pyrazolopyrimidobenzoxazines.



a) POCl₃ / triethylamine, b) Dichloroethane

SCHEME - 1

Results and Discussion

The starting materials, 2 and 6 substituted benzoxazinones (1) required in the present work were prepared by the condensation of 4-substituted-2-aminophenols with suitably substituted α -haloacylhalides in methyl isobutyl ketone in presence of aqueous sodium bicarbonate according to the reported method¹². 1-Aryl-5-aminopyrazole-4-carboxylic acids were prepared by hydrolysis of the corresponding esters. These esters were prepared from reaction of substituted phenylhydrazines with 2-cyano-3-ethoxy propionate according to the reported method¹³.

Our previous work on tetrazolo-¹⁴ and quinazolinobenzoxazines¹⁵ has exemplified the high reactivity of iminochlorides obtained from benzoxazinones towards nucleophiles. Based on this lead, we have now developed a convenient and facile method of converting 1 in a single step into pyrazolopyrimidobenzoxazines (4) via their iminochlorides (2). Thus 1 on reaction with phosphorousoxychloride in dichloroethane at 5° gave the corresponding imino chlorides (2) which underwent smooth cyclocondensation when treated with 5-aminopyrazole-4-carboxylic acids¹³ (3) to give the hitherto unreported new tricyclic ring system namely, pyrazolo[3',4':4,5]pyrimido[2,3-c][1,4]benzoxazines (4a) in 40-50% yields (Scheme -1). The reaction proceeds, presumably via imidoylechloride formation, followed by *in situ* condensation with 5-aminopyrazole-4-carboxylic acid (3) and spontaneous cyclodehydration. The structures of products 4a-l were confirmed by microanalyses, IR, ¹H-NMR and Mass spectra.

TABLE 1- PHYSICAL DATA OF PYRAZOLO[3',4':4,5]PYRIMIDO[2,3-c][1,4]BENZOXAZINES (4)

Compound	R ₁	R ₂	R ₃	4	
				Yield%	m.p °C
a	H	H	H	47	169°
b	H	Cl	H	49	198°
c	H	CH ₃	H	45	208°
d	Cl	H	H	52	187°
e	F	H	H	54	171°
f	F	Cl	H	51	218°
g	CH ₃	H	H	42	224°
h	CH ₃	Cl	H	46	244°
i	H	H	CH ₃	43	192°
j	Cl	H	CH ₃	48	181°
k	CH ₃	H	CH ₃	47	205°
l	COCH ₃	H	H	38	180°

In the $^1\text{H-NMR}$ spectra, the compounds exhibited signals around δ 5.0 for $-\text{OCH}_2$ group of benzoxazine ring, a singlet around δ 8.3 for pyrazole proton and the C_6 proton appeared around δ 8.6 due to peri effect apart from other aromatic protons. Mass spectral fragmentation of compound 4a exhibited a prominent molecular ion peak at m/z 317($m+1$) along with other fragment ions at m/z 288(loss of CO), 196, 143 and 77. The structures of all the compounds reported in Table -1 were based on their IR, $^1\text{H-NMR}$ spectra and correct elemental analyses.

Thus the present method offers a very convenient mild and rapid one step conversion of lactam 1 to the pyrazolo[3',4':4,5]pyrimido[2,3-c][1,4]benzoxazine tricyclic system.

Experimental

Meting points were determined in open capillaries and are uncorrected. IR spectra was recorded in KBr pellets. $^1\text{H-NMR}$ spectra on a varous 200 MHz instrument with TMS as internal standard and chemical shifts are expressed in δ ppm and Mass spectra on a Hewelett Packard Mass Spectrometer operating at 70ev. All the compounds were purified by column chromatography using silica gel.

4,11-Dihydropyrazolo[3',4':4,5]pyrimido[2,3-c][1,4]-benzoxazine-4-one: 4a

To a mixture of 3-oxo-3,4-dihydro-2H-1,4-benzoxazine (1a, 1.49 g, 0.01 mol) in 1,2-dichloroethane (25 ml), phosphorousoxychloride (2.3 g, 0.015 mol) is added dropwise and the mixture is stirred at room temperature for 30 minutes. Triethylamine (1.5 g, 0.015 mol) is added with stirring at $0-5^\circ$, followed by addition of 5-aminopyrazole-4-carboxylicacid (3, $\text{R}_2=\text{H}$, 2.03 g, 0.01 mol), maintaining the temperature at $5-10^\circ$. The mixture is stirred at room temperature for 1 hr and refluxed for 4 hrs on steam bath. The progress of the reaction is followed by TLC. At the end of the reaction, cold water (50 ml) is added to the reaction mixture and the organic layer is separated, washed with water, 10% aqueous sodiumbicarbonate, water, dried and concentrated to give crude 4a. The crude products were purified by column chromatography using silica gel and eluted with a mixture of hexane and ethylacetate (4:1) to give pure 4a as crystalline solid (1.48 g, 47%) mp: 168° ; IR (KBR): 1710 cm^{-1} ms (70ev) m/z (%) 317($M+1$): $^1\text{H-NMR}$ (CDCl_3): δ 5.0 (s, 2H, OCH_2), 7.1-7.6 (m, 6H, ArH) 8.1(m, 2H, ArH) 8.3 (s, 1H, H pyr) 8.6 (dd, 1H, ArH). Anal. Calcd. For $\text{C}_{18}\text{H}_{12}\text{N}_4\text{O}_2$: C, 68.35; H, 3.79; N, 17.72% found C, 68.39; H, 3.82; N, 17.71%.

Compounds 4b-l were similarly prepared the results are tabulated in Table 1.

References:

1. R.F. Frechette & M.J.Beach., *Synth. Commun.*, 28(18), 3471 1998.
2. C.V. Reddy Sastry, K. Srinivasa Rao, V.S.H. Krishnan, K.Rastogi, M.L. Jain, R.K. Varma, R.M. Tripathi, *J. Chem* 28B, 882 1989.

3. C.B. Chapleo, R.C.M. Butler, D.C. England, P.L. Myen, A.G. Roach, C.F.C. Smith, M.R. Stillings, I.F. Tulloch., *J. Med. Chem.*, **32**, 1627 **1989**.
4. D.R. Shridhar, K. Srinivasa Rao, A.N. Singh, K. Rastogi, M.L. Jain, S.S. Gardthi, V.S.H. Krishnan, M. Jogibhukta, C.D. Lorekar, H.N. Tripathi & G.S.T Sai, *Indian. J. Chem.*, **24B**, 1263 **1985**.
5. K. Varaprasad Rao, PSN Reddy & V. Sundara Murthy, *Indian. J. Chem.*, **24B**, 1120 **1985**.
6. D.R. Shridhar, M. Jogibhukta, L.C. Vishwakarma, P.P. Joshi, G.K.A.S.S Narayan, P.P Singh, C. Seshagiri Rao & A Y. Junnarkar, *Indian. J. Chem.*, **23B**, 445 **1984**.
7. C.V. Reddy Sastry, K. Srinivasa Rao, P.P. Singh, C. Seshagiri Rao & A.Y. Junnarkar, *Indian. J. Heterocycl. Chem* **1**, 195 **1992**.
8. Isao Hayakawa, Tokiyuki Hiramitsu & Yoshiaki Tanaka, *Chem. Pharm. Bull.*, **32**, 4907 **1984**.
9. A.R.Kartritzky & C.W. Rees, *Comprehensive Heterocyclic Chemistry* vol **5**, 291 **1984**.
10. T.M. Bilodean, R.W.Hangate, W. Randall, R.L. Kendall, R.Rutleelge, A.K. Thomas, R. Robino, EM Raley, W.O 98, 54, 093, *Chem. Abstr.* **130**, ,1999.
11. K. Srinivasa Rao & C.V. Reddy Sastry., *Indian. J. Heterocyclic Chem.*, **2**, 57, **1992**.
12. D.R. Shridhar, M. Jogibhukta, V.S.H. Krishnan, *Org. Prep. Proced. Int*, **14**(3) 195 **1982**.
13. A. Costanzo, G. Guerrini, F. Bruni & S. Severi, *J. Heterocycl. Chem.* **31**, 1369 **1994**.
14. C.V. Reddy Sastry, K. Srinivasa Rao, V.S.H. Krishnan, K. Rastogi, M.L. Jain, & G.K.A.S.S Narayan, G.S. Reddy, P.P. Singh, C. Seshagiri Rao & A.Y. Junnakar, *Indian. J. Chem.*, **29B**, 396, **1990**.
15. C.V. Reddy Sastry, K. Srinivasa Rao, V.S.H. Krishnan, K. Rastogi & M.L. Jain, *Synthesis* 336 **1988**.
16. Representative ^1H NMR Spectra: **4b**(CDCl_3): δ 4.9(s, 2H, $-\text{OCH}_2$); 7.05(m, 3H, ArH); 7.7(ABquartet, 4H, ArH); 8.2(s, 1H, Hpyr); 8.45(d, 1H, ArH); **4d**(CDCl_3): δ 4.9(s, 2H, OCH_2) 6.9-7.4(m, 5H, ArH); 7.95(m, 2H, ArH); 8.2(s, H, Hpyr); 8.6(d, 1H, ArH). **4i**(CDCl_3): δ 1.8(d, 3H, CH_3); 4.9(q, 1H, O-CH); 7.0-7.6(m, 6H, ArH); 8.1(d, 2H, ArH); 8.25(s, 1H, Hpyr); 8.6(d, 1H, ArH).

Received on April 13, 2003.